JP2012520084A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012520084A5 JP2012520084A5 JP2011554266A JP2011554266A JP2012520084A5 JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5 JP 2011554266 A JP2011554266 A JP 2011554266A JP 2011554266 A JP2011554266 A JP 2011554266A JP 2012520084 A5 JP2012520084 A5 JP 2012520084A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- virus
- protein
- present
- heterologous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 claims description 188
- 210000004027 cell Anatomy 0.000 claims description 60
- 241000124008 Mammalia Species 0.000 claims description 56
- 238000000034 method Methods 0.000 claims description 53
- 241000700605 Viruses Species 0.000 claims description 33
- 230000028993 immune response Effects 0.000 claims description 33
- 108091033319 polynucleotide Proteins 0.000 claims description 32
- 239000002157 polynucleotide Substances 0.000 claims description 32
- 102000040430 polynucleotide Human genes 0.000 claims description 32
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 102000004169 proteins and genes Human genes 0.000 claims description 29
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 24
- 108091007433 antigens Proteins 0.000 claims description 24
- 238000004806 packaging method and process Methods 0.000 claims description 24
- 210000004962 mammalian cell Anatomy 0.000 claims description 23
- 108700004025 env Genes Proteins 0.000 claims description 19
- 101150030339 env gene Proteins 0.000 claims description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 108010087302 Viral Structural Proteins Proteins 0.000 claims description 18
- 230000002519 immonomodulatory effect Effects 0.000 claims description 16
- 229920001184 polypeptide Polymers 0.000 claims description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 16
- 101710172711 Structural protein Proteins 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 241000725619 Dengue virus Species 0.000 claims description 10
- 230000003362 replicative effect Effects 0.000 claims description 10
- 108010003533 Viral Envelope Proteins Proteins 0.000 claims description 9
- 241000711549 Hepacivirus C Species 0.000 claims description 8
- 210000005260 human cell Anatomy 0.000 claims description 8
- 210000000234 capsid Anatomy 0.000 claims description 7
- 230000003612 virological effect Effects 0.000 claims description 7
- 208000006454 hepatitis Diseases 0.000 claims description 6
- 231100000283 hepatitis Toxicity 0.000 claims description 6
- 241001115402 Ebolavirus Species 0.000 claims description 5
- 241000712431 Influenza A virus Species 0.000 claims description 5
- 241000713196 Influenza B virus Species 0.000 claims description 5
- 241001115401 Marburgvirus Species 0.000 claims description 5
- 241000711950 Filoviridae Species 0.000 claims description 4
- 241000710831 Flavivirus Species 0.000 claims description 4
- 241000713666 Lentivirus Species 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 241000712461 unidentified influenza virus Species 0.000 claims description 4
- 238000001727 in vivo Methods 0.000 claims description 3
- 210000004779 membrane envelope Anatomy 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 2
- 101710132601 Capsid protein Proteins 0.000 claims description 2
- 101710177291 Gag polyprotein Proteins 0.000 claims description 2
- 108060003393 Granulin Proteins 0.000 claims description 2
- 101710125418 Major capsid protein Proteins 0.000 claims description 2
- 206010022000 influenza Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 61
- 102100034349 Integrase Human genes 0.000 description 57
- 101710091045 Envelope protein Proteins 0.000 description 31
- 101710188315 Protein X Proteins 0.000 description 31
- 108010061833 Integrases Proteins 0.000 description 30
- 230000001177 retroviral effect Effects 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 15
- 108090000695 Cytokines Proteins 0.000 description 15
- 230000001939 inductive effect Effects 0.000 description 15
- 230000030833 cell death Effects 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 9
- 102100037357 Thymidylate kinase Human genes 0.000 description 8
- 101710102179 Thymidylate kinase Proteins 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 108090000565 Capsid Proteins Proteins 0.000 description 7
- 102100023321 Ceruloplasmin Human genes 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 5
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 102000013462 Interleukin-12 Human genes 0.000 description 5
- 108010065805 Interleukin-12 Proteins 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000000588 Interleukin-2 Human genes 0.000 description 5
- 102000015696 Interleukins Human genes 0.000 description 5
- 108010063738 Interleukins Proteins 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 5
- 102000018697 Membrane Proteins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 244000045947 parasite Species 0.000 description 5
- 244000052769 pathogen Species 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 102000003390 tumor necrosis factor Human genes 0.000 description 5
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 108091030071 RNAI Proteins 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 108700004029 pol Genes Proteins 0.000 description 4
- 101150088264 pol gene Proteins 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 108700004026 gag Genes Proteins 0.000 description 3
- 101150098622 gag gene Proteins 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108020004705 Codon Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000714177 Murine leukemia virus Species 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 241001663880 Gammaretrovirus Species 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 102000010292 Peptide Elongation Factor 1 Human genes 0.000 description 1
- 108010077524 Peptide Elongation Factor 1 Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16028509P | 2009-03-13 | 2009-03-13 | |
| US61/160,285 | 2009-03-13 | ||
| US16676909P | 2009-04-05 | 2009-04-05 | |
| US61/166,769 | 2009-04-05 | ||
| US16708809P | 2009-04-06 | 2009-04-06 | |
| US61/167,088 | 2009-04-06 | ||
| PCT/US2010/027262 WO2010105251A2 (en) | 2009-03-13 | 2010-03-13 | Non-integrating retroviral vector vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012520084A JP2012520084A (ja) | 2012-09-06 |
| JP2012520084A5 true JP2012520084A5 (enExample) | 2013-04-25 |
Family
ID=42729161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011554266A Withdrawn JP2012520084A (ja) | 2009-03-13 | 2010-03-13 | 非組み込み型レトロウイルスベクターワクチン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120135034A1 (enExample) |
| EP (1) | EP2405945A4 (enExample) |
| JP (1) | JP2012520084A (enExample) |
| CN (1) | CN102438658A (enExample) |
| CA (1) | CA2754603A1 (enExample) |
| RU (1) | RU2012140691A (enExample) |
| WO (1) | WO2010105251A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130302368A1 (en) * | 2011-01-27 | 2013-11-14 | Boro Dropulic | Advanced Prime and Boost Vaccine |
| CA2838749A1 (en) * | 2011-06-10 | 2012-12-13 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
| US9713635B2 (en) | 2012-03-30 | 2017-07-25 | Immune Design Corp. | Materials and methods for producing improved lentiviral vector particles |
| CN104583231B (zh) * | 2012-03-30 | 2021-02-26 | 免疫设计公司 | 具有对表达dc-sign的细胞改善的转导效率的慢病毒载体粒子 |
| JP6640717B2 (ja) * | 2013-06-15 | 2020-02-05 | トカジェン インコーポレーテッド | レトロウイルス複製ベクターと関連する免疫抑制成分 |
| EP2878674A1 (en) | 2013-11-28 | 2015-06-03 | Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) | Stable episomes based on non-integrative lentiviral vectors |
| CA2945816A1 (en) | 2014-04-15 | 2015-10-22 | University Of Virginia Patent Foundation | Isolated t cell receptors and methods of use therefor |
| US20180094280A1 (en) * | 2015-03-20 | 2018-04-05 | Bluebird Bio, Inc. | Vector formulations |
| MA41382A (fr) * | 2015-03-20 | 2017-11-28 | Univ Temple | Édition génique basée sur le système crispr/endonucléase à induction par tat |
| WO2017066570A1 (en) * | 2015-10-15 | 2017-04-20 | The University Of North Carolina At Chapel Hill | Methods and compositions for integration-defective lentiviral vectors |
| GB201715052D0 (en) * | 2017-09-19 | 2017-11-01 | Oxford Genetics Ltd | Vectors |
| BR112020011205A8 (pt) | 2017-12-07 | 2023-02-07 | Merck Sharp & Dohme | Formulações de composições de vacina contra o vírus da dengue |
| RU2680537C1 (ru) * | 2018-02-13 | 2019-02-22 | Общество с ограниченной ответственностью "Нанолек" | Лентивирусная плазмида (варианты), способ ее получения (варианты), набор праймеров для получения лентивирусного плазмидного вектора (варианты) |
| RU2681439C1 (ru) * | 2018-02-13 | 2019-03-06 | Общество с ограниченной ответственностью "Нанолек" | Вирусоподобная частица вируса гриппа и способ ее получения |
| RU2681482C1 (ru) * | 2018-02-13 | 2019-03-06 | Общество с ограниченной ответственностью "Нанолек" | MDCK клетка-продуцент белков вируса гриппа (варианты) |
| RU2680703C1 (ru) * | 2018-02-13 | 2019-02-25 | Общество с ограниченной ответственностью "Нанолек" | Кассета, предназначенная для получения плазмидных векторов, используемых для создания клеток-продуцентов вирусоподобных частиц (ВПЧ) вируса гриппа |
| WO2020018715A1 (en) | 2018-07-17 | 2020-01-23 | Massachusetts Institute Of Technology | Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof |
| EP3886759A1 (en) | 2018-11-26 | 2021-10-06 | Massachusetts Institute of Technology | Compositions and methods for immune tolerance |
| JP2022536364A (ja) | 2019-06-13 | 2022-08-15 | ザ ジェネラル ホスピタル コーポレイション | 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法 |
| KR20230043151A (ko) | 2020-07-24 | 2023-03-30 | 더 제너럴 하스피탈 코포레이션 | 증강된 바이러스-유사 입자 및 세포에의 전달을 위한 그의 사용 방법 |
| CA3235865A1 (en) * | 2021-10-25 | 2023-05-04 | Genvivo, Inc. | Compositions and methods for therapeutic or vaccine delivery |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046083A1 (en) * | 1997-04-17 | 1998-10-22 | The Regents Of The University Of California | Use of lentiviral vectors for antigen presentation in dendritic cells |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO2004029246A2 (en) * | 2002-09-26 | 2004-04-08 | K.U.Leuven Research And Development | Integrase cofactor |
| GB0225786D0 (en) * | 2002-11-05 | 2002-12-11 | Glaxo Group Ltd | Vaccine |
| EP2055316A1 (en) * | 2003-09-09 | 2009-05-06 | VIRxSYS Corporation | Lentivirus vector-based approaches for generating an immune response to HIV in humans |
| CN1913919B (zh) * | 2003-09-15 | 2011-10-19 | 美国政府健康及人类服务部 | 基于hiv多进化枝的env的hiv疫苗 |
| FR2872170B1 (fr) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
| JP2008521405A (ja) * | 2004-11-24 | 2008-06-26 | ナノヴェクター・リミテッド | ウイルスベクター |
| EP2573185A3 (en) * | 2005-02-16 | 2013-06-05 | Lentigen Corporation | Lentiviral vectors and their use |
| GB0526211D0 (en) * | 2005-12-22 | 2006-02-01 | Oxford Biomedica Ltd | Viral vectors |
| ES2634144T3 (es) * | 2007-08-03 | 2017-09-26 | Institut Pasteur | Vectores de transferencia lentivíricos defectuosos que no se integran para vacunas |
-
2010
- 2010-03-13 RU RU2012140691/10A patent/RU2012140691A/ru not_active Application Discontinuation
- 2010-03-13 CN CN2010800204988A patent/CN102438658A/zh active Pending
- 2010-03-13 US US13/256,216 patent/US20120135034A1/en not_active Abandoned
- 2010-03-13 JP JP2011554266A patent/JP2012520084A/ja not_active Withdrawn
- 2010-03-13 WO PCT/US2010/027262 patent/WO2010105251A2/en not_active Ceased
- 2010-03-13 CA CA2754603A patent/CA2754603A1/en not_active Abandoned
- 2010-03-13 EP EP10751533A patent/EP2405945A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012520084A5 (enExample) | ||
| US20120135034A1 (en) | Non-Integrating Retroviral Vector Vaccines | |
| JP2018076363A (ja) | レンチウイルス遺伝子導入ベクター及びそれらの医薬品への適用 | |
| JP2013027396A (ja) | クレードＡ／Ｇ、クレードＢ、およびクレードＣ改変ＨＩＶｅｎｖ、ｇａｇ、およびｐｏｌ遺伝子を発現する組換えＭＶＡウイルス | |
| Di Nunzio et al. | HIV-derived vectors for therapy and vaccination against HIV | |
| US20110142880A1 (en) | Lentivirus-based immunogenic vectors | |
| CN104039968B (zh) | 非b亚型gag蛋白在慢病毒包装中的应用 | |
| JP2024502658A (ja) | 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン | |
| CA2825032A1 (en) | Advanced prime and boost vaccine | |
| EP1543837A1 (en) | Virus-like particle (VLP) as vaccine | |
| RU2697781C2 (ru) | Вспомогательный плазмидный лентивирусный экспрессионный вектор для получения высоких титров vpx-содержащих лентивирусных частиц, обеспечивающий эффективное заражение моноцитов и дендритных клеток человека | |
| EUN et al. | Mature HIV-like particles produced from single semliki forest virus-derived expression vector | |
| Wang et al. | Polyvalent DNA prime and envelope protein boost HIV‐1 vaccine elicits humoral and cellular responses and controls... | |
| McKenna | Characterization and immunogenicity of recombinant rhabdoviral vaccine vectors expressing HIV-1 and SIV envelope proteins | |
| HK1200870B (en) | Use of non-subtype b gag proteins for lentiviral packaging |